Health and Healthcare

Amgen : AMGN

All Amgen Articles

701 Articles

Chris Lange | May 1, 2016 at 10:50 AM EDT

Analysts Make Major Changes to Top Biotech Ratings

With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls…

Chris Lange | Apr 27, 2016 at 8:10 AM EDT

Short Sellers Run for Cover From Major Biotechs

The April 15 short interest data have been compared with the previous report, and short interest decreased across the board…

Chris Lange | Apr 12, 2016 at 9:55 AM EDT

Short Sellers Run for Cover From Major Biotechs

The March 31 short interest data have been compared with the previous report, and short interest decreased across the board…

Chris Lange | Mar 16, 2016 at 1:35 PM EDT

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

Regeneron Pharmaceuticals saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen on a cholesterol…

Chris Lange | Mar 10, 2016 at 8:05 AM EST

Short Sellers Back Off of Major Biotechs

The February 29 short interest data have been compared with the previous report, and short interest decreased across the board…

Jon C. Ogg | Feb 25, 2016 at 5:15 PM EST

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four…

Chris Lange | Feb 25, 2016 at 8:46 AM EST

Short Interest Rises Across the Board in Major Biotechs

The February 12 short interest data have been compared with the previous report, and short interest increased across the board…

Chris Lange | Feb 10, 2016 at 8:40 AM EST

Major Biotech Short Interest Continues to Be Mixed

The January 29 short interest data have been compared with the previous report, and short interest was mixed in most…

Lee Jackson | Feb 1, 2016 at 9:50 AM EST

The 4 Largest Biotech Stocks Are Cheaper Than S&P 500

A recent Jefferies research note indicates that the multiples for the four largest biotechs have dipped below that of the…

Chris Lange | Jan 28, 2016 at 4:31 PM EST

Amgen Posts Handy Beat on Estimates and Guidance

Amgen reported better-than-expected fourth-quarter financial results after the markets closed Thursday.

Chris Lange | Jan 28, 2016 at 8:35 AM EST

Short Sellers Increase Bets in Major Biotechs

Short interest increased in most of these selected biotech stocks for the most recent settlement date.

Chris Lange | Jan 20, 2016 at 11:45 AM EST

Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs

Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks…

Chris Lange | Jan 13, 2016 at 8:35 AM EST

Short Interest Remains Mixed for Major Biotechs

The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech…

Jon C. Ogg | Jan 3, 2016 at 10:02 AM EST

10 Top 2016 Stock Picks From Goldman Sachs, Merrill Lynch and Other Key Analysts

Which well-known and large cap stocks to do the major analysts on Wall Street like for 2016? Here are 10.

Jon C. Ogg | Dec 31, 2015 at 8:35 AM EST

5 Top Goldman Sachs Stocks to Buy for 2016

Goldman Sachs has seen many top stocks offering great rewards for 2016. The reason may be different for each, but…

1 … 22 23 24 25 26 … 47

Amgen : AMGN

All Amgen Articles

Analysts Make Major Changes to Top Biotech Ratings

Short Sellers Run for Cover From Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

Short Sellers Back Off of Major Biotechs

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Short Interest Rises Across the Board in Major Biotechs

Major Biotech Short Interest Continues to Be Mixed

The 4 Largest Biotech Stocks Are Cheaper Than S&P 500

Amgen Posts Handy Beat on Estimates and Guidance

Short Sellers Increase Bets in Major Biotechs

Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs

Short Interest Remains Mixed for Major Biotechs

10 Top 2016 Stock Picks From Goldman Sachs, Merrill Lynch and Other Key Analysts

5 Top Goldman Sachs Stocks to Buy for 2016

Why Is Institutional Money Pouring Into XRP ETFs While Fleeing Bitcoin and Ethereum?

U.S. Interest Expense Just Hit $1.6 Trillion Annually. Peter Schiff Warns a Dollar Crisis Arrives When It Hits $2 Trillion.

70-Year-Old Couple With $1.8M Just Got a Stage 2 Cancer Diagnosis. Financial Decisions They Have 60 Days to Make

70-Year-Old Couple With $1.8M Just Got a Stage 2 Cancer Diagnosis. Financial Decisions They Have 60 Days to Make

64-Year-Old Tech Exec Holds $1.6 Million in One Stock. The Wrong Move Could Cost $400,000.

Why Is Institutional Money Pouring Into XRP ETFs While Fleeing Bitcoin and Ethereum?

U.S. Interest Expense Just Hit $1.6 Trillion Annually. Peter Schiff Warns a Dollar Crisis Arrives When It Hits $2 Trillion.

Amgen : AMGN

All Amgen Articles

Analysts Make Major Changes to Top Biotech Ratings

Short Sellers Run for Cover From Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

Short Sellers Back Off of Major Biotechs

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Short Interest Rises Across the Board in Major Biotechs

Major Biotech Short Interest Continues to Be Mixed

The 4 Largest Biotech Stocks Are Cheaper Than S&P 500

Amgen Posts Handy Beat on Estimates and Guidance

Short Sellers Increase Bets in Major Biotechs

Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs

Short Interest Remains Mixed for Major Biotechs

10 Top 2016 Stock Picks From Goldman Sachs, Merrill Lynch and Other Key Analysts

5 Top Goldman Sachs Stocks to Buy for 2016

Why Is Institutional Money Pouring Into XRP ETFs While Fleeing Bitcoin and Ethereum?

U.S. Interest Expense Just Hit $1.6 Trillion Annually. Peter Schiff Warns a Dollar Crisis Arrives When It Hits $2 Trillion.

70-Year-Old Couple With $1.8M Just Got a Stage 2 Cancer Diagnosis. Financial Decisions They Have 60 Days to Make

Featured Reads

70-Year-Old Couple With $1.8M Just Got a Stage 2 Cancer Diagnosis. Financial Decisions They Have 60 Days to Make

64-Year-Old Tech Exec Holds $1.6 Million in One Stock. The Wrong Move Could Cost $400,000.